KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Financing Activities: 2010-2024

Historic Cash from Financing Activities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $12.2 million.

  • Supernus Pharmaceuticals' Cash from Financing Activities rose 585.14% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 12.18%. This contributed to the annual value of $12.2 million for FY2024, which is 103.06% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $12.2 million for FY2024, which was up 103.06% from -$397.9 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Cash from Financing Activities peaked at $12.2 million during FY2024, and registered a low of -$397.9 million during FY2023.
  • Moreover, its 3-year median value for Cash from Financing Activities was -$10.5 million (2022), whereas its average is -$132.1 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 3,764.51% in 2021, then spiked by 103.06% in 2024.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Cash from Financing Activities stood at $3.6 million in 2020, then tumbled by 3,764.51% to -$130.4 million in 2021, then soared by 91.97% to -$10.5 million in 2022, then plummeted by 3,697.65% to -$397.9 million in 2023, then skyrocketed by 103.06% to $12.2 million in 2024.